Many therapeutic drug molecules generally contain a chiral centre. In the drug molecule containing a single chiral centre one enantiomer may possess the desired pharmaceutical activity while the other enantiomer may be either inactive or exhibit undesirable effect. It is dangerous to administer the inactive enantiomer as the drug. Thus identification, separation and the quantification of enantiomeric excess of one form over the other is of paramount importance in the pharmaceutical industry and also in asymmetric synthesis. An achiral solvent normally employed in solution state NMR does not permit the differentiation of the two enantiomers. Aligning the molecule in a chiral liquid crystalline phase, on the other hand, overcomes this difficulty. Employment of proton detection for such a purpose is severely hampered due to significant loss of resolution arising from the unresolved transitions due to several short and long distance dipolar couplings and the doubling of the spectra from the two enantiomers. In recent times we have developed several novel NMR methodologies to circumvent some of these problems. The remarkable spectral simplification achieved, by discerning the degenerate transitions, enables the determination of spectral parameters from the broad and featureless 1H spectra. The developed methodologies not only aid in unambiguous visualization of enantiomers but also permit the measure of enantiomeric excess. The results of our recent study will be discussed.
References
1. Uday Ramesh Prabhu and N. Suryaprakash, J. Magn. Reson. 202, 217-222 (2010)
2.Nilamoni Nath and N. Suryaprakash, J. Magn. Reson. 202, 34-37 (2010)
3.Nilamoni Nath, Bikash Baishya and N. Suryaprakash, J. Magn. Reson. 200, 101-108 (2009)
4.Uday Ramesh Prabhu and N. Suryaprakash, J. Magn. Reson. 195, 145-152 (2008)
5.Uday Ramesh Prabhu, Bikash Baishya and N. Suryaprakash, J. Phys. Chem. A. 112, 5658-5669 (2008)
6.Bikash Baishya, Uday Ramesh Prabhu and N. Suryaprakash, J. Magn. Reson. 192, 101-111 (2008)
|